WebApr 3, 2024 · Medicare Expands Coverage for Hologic's Biotheranostics Breast Cancer Test. The firm said that the expanded coverage provides more women with access to a test that helps determine whether extended endocrine therapy is appropriate. Hologic Banking on MDx Acquisitions to Elevate Long-Term Revenue Growth. WebFeb 23, 2024 · February 23, 2024 By Sean Whooley. Hologic (NSDQ: HOLX) announced that it completed its previously announced acquisition of Biotheranostics for $230 million. Marlborough, Mass.-based Hologic last ...
Breast Cancer Index
WebJan 6, 2024 · January 6, 2024 By Sean Whooley. Hologic (NSDQ: HOLX) announced that it agreed to acquire molecular diagnostic test maker Biotheranostics for approximately $230 million. Privately held, commercial ... WebAccess and use of the Biotheranostics Web site is subject to the terms and conditions set forth herein and all applicable laws, statutes, and/or regulations. Biotheranostics does not, by or through this Web site, offer for sale any products or services. Biotheranostics may revise or modify these terms and conditions from time to time. portland maine cruises to canada
CancerTYPE ID® NeoGenomics Laboratories
WebJan 5, 2024 · On January 5, 2024, Hologic acquired life science company Biotheranostics for 230M USD Acquisition Highlights. This is Hologic’s 2nd transaction in the Life Science sector. This is Hologic’s 7th largest (disclosed) transaction. This is Hologic’s 15th transaction in the United States. This is Hologic’s 4th transaction in California. WebJan 5, 2024 · Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing … WebJan 5, 2024 · MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, … optics tir